The MHRA has approved acoramidis (Beyonttra) for treating transthyretin amyloid cardiomyopathy (ATTR-CM) in adults, offering new hope to around 800 UK patients.
This fast-track approval, granted on April 24, 2025, leverages the International Recognition Procedure to expedite access following EMA approval.
Accelerated Access and Patient Benefits
The approval of acoramidis marks a significant advancement in the treatment of ATTR-CM, a rare and life-threatening heart condition.
By stabilizing misfolded transthyretin proteins, this oral medication aims to slow heart damage and improve patient outcomes.
The decision was based on a robust clinical trial involving 632 participants, which demonstrated a 77% higher benefit rate over placebo.
Positive Outcomes for Patients
- Targets approximately 800 UK patients with wild-type or hereditary ATTR-CM.
- Improves survival rates and reduces hospitalizations.
- Demonstrates efficacy in mortality reduction and cardiovascular hospitalization over 30 months.
- Enhances quality of life by reducing the frequency of hospital visits.
Regulatory Innovation: A New Era for Rare Disease Treatment
This approval aligns with the MHRA’s post-Brexit strategy to expedite access to globally recognized treatments.
By leveraging the International Recognition Procedure, the MHRA ensures quicker availability of essential medications while maintaining rigorous safety standards through ongoing monitoring via its Yellow Card scheme.
Julian Beach from MHRA emphasized their commitment to providing faster access to medicines that can significantly impact patients’ lives.
Julian Beach, MHRA Interim Executive Director, Healthcare Quality and Access, said:
“Keeping patients safe and enabling their access to high quality, safe and effective medical products are key priorities for us.
“The approval of acoramidis reflects our ongoing commitment to ensuring quicker access to medicines that can make a real difference to people suffering from serious diseases, and that have proven safety, quality and efficacy recognised by comparable international regulators.
“We’re assured that the appropriate regulatory standards for the approval of this medicine have been met.
“As with all products, we will keep the safety of acoramidis under close review.”
A Global Perspective on Acoramidis
The UK’s alignment with EMA approvals strengthens its role in global rare disease treatment networks.
Similar FDA approvals suggest that acoramidis could set a benchmark for future amyloidosis therapies, influencing EU-UK regulatory collaboration post-Brexit.
This development highlights the importance of international cooperation in addressing rare diseases effectively.
Additional Reading
A Final Reflection
The approval of acoramidis represents a pivotal moment for those affected by ATTR-CM in the UK. As this medication becomes available, it promises not only improved health outcomes but also reduced strain on healthcare services.
Continued monitoring will ensure its safe integration into treatment protocols, offering hope for better management of this challenging condition.
Discover more of Todays Top Breaking News Stories!
Sources: UK Government, PubMed, Bayer, and Medicines and Healthcare products Regulatory Agency.
Prepared by Ivan Alexander Golden, Founder of THX News™, an independent news organization delivering timely insights from global official sources. Combines AI-analyzed research with human-edited accuracy and context.
